Trial · NCT04802161
Adverse events1,164
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,164
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Alanine Aminotransferase Increased | Investigations | Safety Run In DL1 (14 Days Pomalidomide) | 4 | 7 | 17 |
| other | Alanine Aminotransferase Increased | Investigations | Safety Run In DL-1 (10 Days Pomalidomide) | 2 | 3 | 10 |
| other | Alanine Aminotransferase Increased | Investigations | Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide) | 8 | 20 | 24 |
| other | Alanine Aminotransferase Increased | Investigations | Arm B (Daunorubicin and Cytarabine Liposome) | 8 | 19 | 27 |
| other | Aspartate Aminotransferase Increased | Investigations | Safety Run In DL1 (14 Days Pomalidomide) | 6 | 7 | 25 |
| other | Aspartate Aminotransferase Increased | Investigations | Safety Run In DL-1 (10 Days Pomalidomide) | 2 | 3 | 16 |
| other | Aspartate Aminotransferase Increased | Investigations | Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide) | 8 | 20 | 34 |
| other | Aspartate Aminotransferase Increased | Investigations | Arm B (Daunorubicin and Cytarabine Liposome) | 8 | 19 | 36 |
| other | Abdominal distension | Gastrointestinal disorders | Safety Run In DL1 (14 Days Pomalidomide) | 0 | 7 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Safety Run In DL-1 (10 Days Pomalidomide) | 0 | 3 | 0 |
| other | Abdominal distension | Gastrointestinal disorders | Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide) | 1 | 20 | 1 |
| other | Abdominal distension | Gastrointestinal disorders | Arm B (Daunorubicin and Cytarabine Liposome) | 0 | 19 | 0 |
| other | Abdominal Pain | Gastrointestinal disorders | Safety Run In DL1 (14 Days Pomalidomide) | 1 | 7 | 1 |
| other | Abdominal Pain | Gastrointestinal disorders | Safety Run In DL-1 (10 Days Pomalidomide) | 1 | 3 | 2 |
| other | Abdominal Pain | Gastrointestinal disorders | Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide) | 6 | 20 | 12 |
| other | Abdominal Pain | Gastrointestinal disorders | Arm B (Daunorubicin and Cytarabine Liposome) | 1 | 19 | 1 |
| other | Activated Partial Thromboplastin Time Prolonged | Investigations | Safety Run In DL1 (14 Days Pomalidomide) | 0 | 7 | 0 |
| other | Activated Partial Thromboplastin Time Prolonged | Investigations | Safety Run In DL-1 (10 Days Pomalidomide) | 0 | 3 | 0 |
| other | Activated Partial Thromboplastin Time Prolonged | Investigations | Arm A (Daunorubicin and Cytarabine Liposome, Pomalidomide) | 2 | 20 | 2 |
| other | Activated Partial Thromboplastin Time Prolonged | Investigations | Arm B (Daunorubicin and Cytarabine Liposome) | 0 | 19 | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04802161/events